ensovibep

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Apr 1, 2021 → Aug 20, 2021

About ensovibep

ensovibep is a phase 2 stage product being developed by Molecular Partners for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04834856. Target conditions include Covid19.

What happened to similar drugs?

4 of 16 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (9)

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04834856Phase 2Completed